Private Company R&D Expenditures
Industry Overview |
WA BioHistory Poster |
WA BioEvolution/Genealogy Poster |
Employment
Capital Availability |
Revenue & Income |
Research
Biotechnology Company
R&D Expenditures, 2003-2004
| Name |
2003 |
2004 |
R&D Per Emp |
Actual Chg |
% Chg |
Cell Therapeutics,
Inc. |
$89,534,000 |
$101,127,000 |
$393,490 |
$11,593,000 |
13% |
| Dendreon Corp. |
$38,900,000 |
$64,400,000 |
$348,108 |
$25,500,000 |
66% |
| EDEN Bioscience |
$4,900,000 |
$3,505,000 |
$87,625 |
($1,395,000) |
-28% |
| Helix Biomedix, Inc. |
$884,450 |
$915,157 |
$101,684 |
$70,707 |
8% |
ICOS Corp. |
$85,758,000 |
$71,791,000 |
$146,512 |
($13,967,000) |
-16% |
Life Systems Corp. |
n/a |
n/a |
n/a |
n/a |
n/a |
Lumera, Inc. |
$7,602,000 |
$4,561,000 |
$120,026 |
($3,041,000) |
-40% |
Nastech Pharmaceutical |
$17,097,000 |
$21,083,000 |
$226,699 |
$3,986,000 |
23% |
NeoRx Corp. |
$9,591,000 |
$13,300,000 |
$403,030 |
$3,709,000 |
39% |
| Northwest Biotherapeutics |
$1,634,000 |
$3,621,000 |
$452,625 |
$1,987,000 |
122% |
| SCOLR (formerly Nutraceutix, Inc.) |
$403,186 |
$2,603,361 |
$216,947 |
$2,200,175 |
546% |
ProCyte Corp. |
n/a |
n/a |
n/a |
n/a |
n/a |
| Seattle Genetics |
$21,390,000 |
$37,002,000 |
$276,134 |
$15,612,000 |
73% |
Targeted Genetics |
$17,197,000 |
$17,288,000 |
$216,100 |
$91,000 |
1% |
Xcyte Therapies |
$13,685,000 |
$19,698,000 |
$231,741 |
$6,013,000 |
44% |
ZymoGenetics |
$63,464,000 |
$94,287,000 |
$235,718 |
$30,823,000 |
49% |
Total - Biotechnology |
$371,999,636 |
$455,181,518 |
$238,565 |
$83,181,882 |
22% |
Medical Device
Company R&D Expenditures, 2003-2004
Name |
2003 |
2004 |
R&D Per Emp |
Actual Chg. |
% Chg. |
Microvision |
$23,316,000 |
$14,710,000 |
$88,614 |
$12,378,600 |
-37% |
SonoSite, Inc. |
$11,179,000 |
$12,644,000 |
$53,804 |
($2,698,025) |
13% |
Sonus Pharmaceuticals |
$7,700,000 |
$10,700,000 |
$222,917 |
($2,327,358) |
39% |
Total - Medical Device |
$42,195,000 |
$38,054,000 |
$46,635 |
($4,141,000) |
-44% |
Information is believed accurate but is not guaranteed.
Back to Research
|
